
Globus Medical, Inc. (GMED) Q2 2026 Earnings Call Transcript
Globus Medical, Inc. (GMED) Q2 2026 Earnings Call Transcript
Latest financial and economic news and analysis

Globus Medical, Inc. (GMED) Q2 2026 Earnings Call Transcript

Texas Roadhouse, Inc. (TXRH) Q2 2026 Earnings Call Transcript

A judge in New Mexico ordered Meta to pay $567 million into an abatement fund after a jury ruled the company willfully violated the state's unfair practices act. Meta's platforms are contributing to the "current mental health crisis among New Mexico's youth," the judge wrote in the filing on Thursday.

BRC Group Holdings, Inc. (RILY) Q2 2026 Earnings Call Transcript

Aspen Aerogels, Inc. (ASPN) Q2 2026 Earnings Call Transcript

Burford Capital Limited (BUR) Q2 2026 Earnings Call Transcript

HCI Group (HCI) came out with quarterly earnings of $5.6 per share, beating the Zacks Consensus Estimate of $4.97 per share. This compares to earnings of $5.18 per share a year ago.

Inogen (INGN) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.15 per share a year ago.

Mach Natural Resources LP (MNR) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of $0.34 per share. This compares to earnings of $0.76 per share a year ago.

Onto Innovation (ONTO) came out with quarterly earnings of $1.93 per share, beating the Zacks Consensus Estimate of $1.68 per share. This compares to earnings of $1.25 per share a year ago.

Morgan Stanley Direct Lending Fund (MSDL) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.5 per share a year ago.

ICU Medical (ICUI) came out with quarterly earnings of $2.37 per share, beating the Zacks Consensus Estimate of $1.91 per share. This compares to earnings of $2.1 per share a year ago.

The RealReal has spent the past year rebuilding its core operations around artificial intelligence, and growth has been accelerating alongside it.

U.S. Physical Therapy, Inc. remains rated Hold as operational growth is offset by disappointing profitability and fair valuation. USPH exceeded revenue expectations in Q2 2026, but EPS fell short due to one-time events and rising costs. Clinic expansion, hospital affiliations, and industrial injury prevention services are driving top-line growth and future margin improvement.

Oil rose in early Asian trade amid concerns over supply disruptions in the Middle East.